| scholarly article | Q13442814 |
| P50 | author | Dan Peer | Q43193344 |
| P2093 | author name string | N Manjunath | |
| Katsuyoshi Habiro | |||
| Premlata Shankar | |||
| Priti Kumar | |||
| Sang-Soo Kim | |||
| Yong-Guang Yang | |||
| Motomu Shimaoka | |||
| Sandesh Subramanya | |||
| Deshratan Asthana | |||
| Huaquan Wu | |||
| P2860 | cites work | T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice | Q24603574 |
| Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging | Q25255924 | ||
| Asymmetry in the assembly of the RNAi enzyme complex | Q27860763 | ||
| Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target | Q28266775 | ||
| miRNA profiling of naïve, effector and memory CD8 T cells. | Q33302117 | ||
| Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model. | Q33781391 | ||
| Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals | Q33816825 | ||
| Human immunodeficiency virus type 1 strains R5 and X4 induce different pathogenic effects in hu-PBL-SCID mice, depending on the state of activation/differentiation of human target cells at the time of primary infection. | Q33816889 | ||
| HIV entry inhibitors and their potential in HIV therapy | Q34595921 | ||
| Transvascular delivery of small interfering RNA to the central nervous system. | Q34638044 | ||
| Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages | Q35149275 | ||
| Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. | Q35676793 | ||
| Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice. | Q35784905 | ||
| Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV | Q35847908 | ||
| Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates | Q35928777 | ||
| Activation of the mammalian immune system by siRNAs. | Q36307323 | ||
| RNAi as a treatment for HIV-1 infection. | Q36455689 | ||
| Interfering antiviral immunity: application, subversion, hope? | Q36497229 | ||
| HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/- (RAG-hu) mouse model | Q38905274 | ||
| LFA-1 expression on target cells promotes human immunodeficiency virus type 1 infection and transmission | Q39601711 | ||
| Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. | Q40214644 | ||
| The binding sites for competitive antagonistic, allosteric antagonistic, and agonistic antibodies to the I domain of integrin LFA-1. | Q40517700 | ||
| siRNA-directed inhibition of HIV-1 infection | Q40727988 | ||
| Chemokine (C-C motif) receptor 5 entry inhibitors: new class of drugs for acquired immune deficiency syndrome | Q43806067 | ||
| Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes | Q44428946 | ||
| Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models | Q44706686 | ||
| Physicochemical evaluation of a stability-driven approach to drug entrapment in regular and in surface-modified liposomes | Q47619451 | ||
| Asymmetric RNA duplexes mediate RNA interference in mammalian cells. | Q53436494 | ||
| Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA | Q81547115 | ||
| Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors | Q81772313 | ||
| Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation | Q82252349 | ||
| P433 | issue | 2 | |
| P921 | main subject | nanoparticle | Q61231 |
| P304 | page(s) | 370-376 | |
| P577 | publication date | 2009-12-08 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice | |
| P478 | volume | 18 |
| Q38095502 | A daunting task: manipulating leukocyte function with RNAi |
| Q30431343 | A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. |
| Q36811931 | APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication |
| Q28080090 | Achieving HIV-1 Control through RNA-Directed Gene Regulation |
| Q53100671 | Adding Functions to Biomaterial Surfaces through Protein Incorporation. |
| Q40735074 | Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles. |
| Q38144256 | Advances in siRNA delivery to T-cells: potential clinical applications for inflammatory disease, cancer and infection |
| Q36341433 | Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery Systems |
| Q26777022 | Animal and human mucosal tissue models to study HIV biomedical interventions: can we predict success? |
| Q35144394 | Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells |
| Q37914065 | Antiviral RNAi: translating science towards therapeutic success |
| Q36870444 | Antiviral Stratagems Against HIV-1 Using RNA Interference (RNAi) Technology |
| Q35998374 | BLT humanized mice as a small animal model of HIV infection |
| Q38884364 | Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection |
| Q47236016 | Cell and Gene Therapy for HIV Cure |
| Q28385606 | Cell delivery of therapeutic nanoparticles |
| Q37850458 | Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis |
| Q34734219 | Chemokine receptor 5 knockout strategies |
| Q26866145 | Combinatorial RNA-based gene therapy for the treatment of HIV/AIDS |
| Q30420558 | Controlling the HIV/AIDS epidemic: current status and global challenges |
| Q39230061 | Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes |
| Q34474320 | Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis |
| Q37940340 | Current progress in the development of RNAi-based therapeutics for HIV-1 |
| Q28235733 | Current prospects for RNA interference-based therapies |
| Q38205757 | Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles. |
| Q21133769 | Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice |
| Q37205125 | Engineering nano- and microparticles to tune immunity |
| Q34982851 | Ex vivo gene therapy for HIV-1 treatment |
| Q38365989 | Expression of chimeric receptor CD4ζ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. |
| Q36512567 | Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge |
| Q35666126 | Generation of HIV latency in humanized BLT mice |
| Q47555792 | Glycosyl-phosphatidylinositol-Anchored Anti-HIV Env Single Chain Variable Fragments Interfere with HIV-1 Env Processing and Viral Infectivity |
| Q47578379 | Grand challenges in modulating the immune response with RNAi nanomedicines. |
| Q37676228 | HIV-1 immunopathogenesis in humanized mouse models |
| Q35673875 | Harnessing RNAi nanomedicine for precision therapy |
| Q36459323 | Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. |
| Q27023434 | Hematopoietic-stem-cell-based gene therapy for HIV disease |
| Q37252004 | Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches |
| Q42254467 | Human immune system development and survival of non-obese diabetic (NOD)-scid IL2rγ(null) (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells |
| Q37111994 | Humanized mice for immune system investigation: progress, promise and challenges |
| Q37089865 | Humanized mouse models of HIV infection |
| Q35848314 | In vivo analysis of Nef's role in HIV-1 replication, systemic T cell activation and CD4(+) T cell loss |
| Q30009533 | In vivo analysis of highly conserved Nef activities in HIV-1 replication and pathogenesis |
| Q33687594 | Intranasal drug delivery of small interfering RNA targeting Beclin1 encapsulated with polyethylenimine (PEI) in mouse brain to achieve HIV attenuation |
| Q26859021 | Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives |
| Q59354268 | Masters of manipulation: Viral modulation of the immunological synapse |
| Q34920166 | Mice with human immune system components as in vivo models for infections with human pathogens |
| Q37358577 | Microvascular targets for anti-fibrotic therapeutics |
| Q30488022 | Molecular and Cellular Therapies: New challenges and opportunities |
| Q91813244 | Moving beyond the mousetrap: current and emerging humanized mouse and rat models for investigating prevention and cure strategies against HIV infection and associated pathologies |
| Q36923075 | Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice |
| Q38823456 | Nano-ART and NeuroAIDS. |
| Q89834871 | Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers |
| Q37481839 | Nanoparticles containing siRNA to silence CD4 and CCR5 reduce expression of these receptors and inhibit HIV-1 infection in human female reproductive tract tissue explants |
| Q38622404 | Nanotechnology Approaches for the Delivery of Exogenous siRNA for HIV Therapy |
| Q35943647 | Nanotechnology and the treatment of HIV infection. |
| Q59359574 | Nanotechnology approaches to eradicating HIV reservoirs |
| Q36112824 | Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4+CD8+ thymocytes. |
| Q40102925 | New approaches for the enhancement of chimeric antigen receptors for the treatment of HIV. |
| Q27014786 | New generation humanized mice for virus research: comparative aspects and future prospects |
| Q27013957 | Novel approaches to inhibit HIV entry |
| Q38048762 | Novel cell and gene therapies for HIV. |
| Q35140303 | One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates |
| Q47225568 | Optimization and comparison of CD4-targeting lipid-polymer hybrid nanoparticles using different binding ligands. |
| Q98292337 | Pharmaceutical Approaches to HIV Treatment and Prevention |
| Q39600778 | Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor |
| Q38475224 | Progress in RNAi-mediated Molecular Therapy of Acute and Chronic Myeloid Leukemia |
| Q36161380 | Progress on RNAi-based molecular medicines |
| Q38260862 | Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs |
| Q35652119 | RNA interference approaches for treatment of HIV-1 infection |
| Q37678411 | RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? |
| Q38249163 | RNA-based drugs and vaccines |
| Q37941651 | RNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside. |
| Q33565464 | RNAi reduces expression and intracellular retention of mutant cartilage oligomeric matrix protein |
| Q37866632 | RNAi-based therapeutic strategies for metabolic disease |
| Q38788187 | Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS. |
| Q28488527 | Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice |
| Q42925805 | Reprogramming immune responses via microRNA modulation |
| Q33777250 | Riding in silence: a little snowboarding, a lot of small RNAs |
| Q38256787 | Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies |
| Q37864924 | Special delivery: targeted therapy with small RNAs. |
| Q34769333 | Stem cell-based anti-HIV gene therapy |
| Q36053809 | Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells. |
| Q35623481 | Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice |
| Q26866079 | T-cell therapies for HIV |
| Q24620150 | Targeted DNA mutagenesis for the cure of chronic viral infections |
| Q52579251 | Targeting Accessories to the Crime: Nanoparticle Nucleic Acid Delivery to the Tumor Microenvironment. |
| Q38239575 | Targeting strategies for delivery of anti-HIV drugs |
| Q37350713 | The feasibility of incorporating Vpx into lentiviral gene therapy vectors. |
| Q35206268 | The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment |
| Q38867794 | Toward RNA nanoparticle vaccines: synergizing RNA and inorganic nanoparticles to achieve immunopotentiation |
| Q47570622 | Toxicity profiling of several common RNAi-based nanomedicines: a comparative study |
| Q38405327 | Vaccine nanoparticles for protection against HIV infection |
| Q35876209 | Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment |
Search more.